NeOnc Technologies is a clinical-stage CNS oncology company developing therapies designed to overcome the blood-brain barrier (BBB) and improve drug delivery to the brain. The Company’s lead program, NEO212, is a next-generation version of temozolomide (TMZ), the standard-of-care chemotherapy used in most brain cancer patients. It is designed to address key limitations of current treatment including BBB penetration and MGMT-driven resistance. Its platform includes NEO100 and NEO212, discussed in further detail below. Beyond its lead programs, NeOnc’s platform approach combines intranasal and oral drug delivery technologies designed to improve CNS drug penetration, supporting additional opportunities across multiple brain tumor indications. Lastly, NTHI recently led a successful PIPE offering, adding a gross $16.0M to the Company’s balance sheet.